CHINARES PHARMA (03320) Considers RMB0.51 Billion Sale of 5.88% Stake in Tianmai Biotechnology

Bulletin Express

Mar 16

China Resources Pharmaceutical Group Ltd. (CHINARES PHARMA, stock code 03320) disclosed that its wholly owned subsidiary, China Resources Pharmaceutical Investment Co., has launched a public tender to dispose of approximately 5.88% equity in Tianmai Biotechnology Development Co., Ltd.

The proposed sale will be conducted on the Shanghai United Assets and Equity Exchange with an initial minimum listing price of about RMB0.51 billion. The tender process is separate from an earlier transaction involving Tianmai Biotechnology announced on 9 February 2026.

As at the announcement date, China Resources Pharmaceutical Investment and its subsidiary collectively hold around 23.75% of Tianmai Biotechnology. Identification of a transferee and execution of definitive agreements remain pending; if no transferee emerges, the tender will lapse automatically.

The company stated it will comply with Chapter 14 of the Hong Kong Listing Rules once transaction agreements, if any, are signed. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/1168835349"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1168835349\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1168835349?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-03-16 22:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1168835349","market":"us","top_or_hot":-1,"title":"CHINARES PHARMA (03320) Considers RMB0.51 Billion Sale of 5.88% Stake in Tianmai Biotechnology","media":"Bulletin Express","content":"<p>China Resources Pharmaceutical Group Ltd. (CHINARES PHARMA, stock code 03320) disclosed that its wholly owned subsidiary, China Resources Pharmaceutical Investment Co., has launched a public tender to dispose of approximately 5.88% equity in Tianmai Biotechnology Development Co., Ltd.</p>\n<p>The proposed sale will be conducted on the Shanghai United Assets and Equity Exchange with an initial minimum listing price of about RMB0.51 billion. The tender process is separate from an earlier transaction involving Tianmai Biotechnology announced on 9 February 2026.</p>\n<p>As at the announcement date, China Resources Pharmaceutical Investment and its subsidiary collectively hold around 23.75% of Tianmai Biotechnology. Identification of a transferee and execution of definitive agreements remain pending; if no transferee emerges, the tender will lapse automatically.</p>\n<p>The company stated it will comply with Chapter 14 of the Hong Kong Listing Rules once transaction agreements, if any, are signed. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CHINARES PHARMA (03320) Considers RMB0.51 Billion Sale of 5.88% Stake in Tianmai Biotechnology</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCHINARES PHARMA (03320) Considers RMB0.51 Billion Sale of 5.88% Stake in Tianmai Biotechnology\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-03-16 22:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>China Resources Pharmaceutical Group Ltd. (CHINARES PHARMA, stock code 03320) disclosed that its wholly owned subsidiary, China Resources Pharmaceutical Investment Co., has launched a public tender to dispose of approximately 5.88% equity in Tianmai Biotechnology Development Co., Ltd.</p>\n<p>The proposed sale will be conducted on the Shanghai United Assets and Equity Exchange with an initial minimum listing price of about RMB0.51 billion. The tender process is separate from an earlier transaction involving Tianmai Biotechnology announced on 9 February 2026.</p>\n<p>As at the announcement date, China Resources Pharmaceutical Investment and its subsidiary collectively hold around 23.75% of Tianmai Biotechnology. Identification of a transferee and execution of definitive agreements remain pending; if no transferee emerges, the tender will lapse automatically.</p>\n<p>The company stated it will comply with Chapter 14 of the Hong Kong Listing Rules once transaction agreements, if any, are signed. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03320","symbol_name":"华润医药","start_time":0,"source_url":"","article_id":"1168835349","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1168835349","pubTimestamp":1773670925,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"China Resources Pharmaceutical Group Ltd. (CHINARES PHARMA, stock code 03320) disclosed that its wholly owned subsidiary, China Resources Pharmaceutical Investment Co., has launched a public tender...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03320":"华润医药"},"translate_title":"CHINARES PHARMA(03320)考虑以人民币5.1亿元出售天迈生物5.88%股权","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03320":1},"content_text":"China Resources Pharmaceutical Group Ltd. (CHINARES PHARMA, stock code 03320) disclosed that its wholly owned subsidiary, China Resources Pharmaceutical Investment Co., has launched a public tender to dispose of approximately 5.88% equity in Tianmai Biotechnology Development Co., Ltd.\nThe proposed sale will be conducted on the Shanghai United Assets and Equity Exchange with an initial minimum listing price of about RMB0.51 billion. The tender process is separate from an earlier transaction involving Tianmai Biotechnology announced on 9 February 2026.\nAs at the announcement date, China Resources Pharmaceutical Investment and its subsidiary collectively hold around 23.75% of Tianmai Biotechnology. Identification of a transferee and execution of definitive agreements remain pending; if no transferee emerges, the tender will lapse automatically.\nThe company stated it will comply with Chapter 14 of the Hong Kong Listing Rules once transaction agreements, if any, are signed. Shareholders and potential investors are advised to exercise caution when dealing in the company’s securities.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}